Reported positive YTD 2024 Adjusted EBITDA of $1.4 million

Company expects Q4 2024 Net Revenue in the range of $37 million – $43 million

ZYNRELEF® (bupivacaine and meloxicam) extended-release solution Vial Access Needle (“VAN”) approved in September and on track for Q4 2024 launch

CMS Final Rule Non-Opioid Policy for Pain Relief includes ZYNRELEF as a qualifying product for separate payment in both the hospital outpatient department and ambulatory surgical center settings of care

SAN DIEGO , Nov. 12, 2024 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and nine months ended September 30, 2024, and highlighted recent corporate updates. “We are pleased to report that with our prudent financial management and continued revenue growth we were able to achieve positive Adjusted EBITDA for the quarter,” said Craig Collard, Chief Executive Officer.

With the reported positive YTD Adjusted EBITDA of $1.4 million and the Company’s expectation of Q4 2024 Net Revenue in the range of $37 million – $43 million, Heron Therapeutics is poised for continued growth in the biotechnology sector. The approval and upcoming launch of ZYNRELEF® in September further solidifies the company’s position in the market, particularly with the inclusion of the product in CMS Final Rule Non-Opioid Policy for Pain Relief.

The approval and market launch of ZYNRELEF® is a significant milestone for Heron Therapeutics, as it opens up new opportunities for revenue growth and establishes the company as a key player in non-opioid pain relief solutions. The inclusion of ZYNRELEF® in CMS Final Rule further enhances its market potential and solidifies its position as a qualifying product for separate payment in various healthcare settings.

How this will affect me:

As a consumer, the approval and launch of ZYNRELEF® can potentially provide me with access to a non-opioid pain relief solution that is recognized by CMS for separate payment in healthcare settings. This can result in improved access to innovative pain management options and potentially lead to better outcomes for individuals seeking alternative pain relief treatments.

How this will affect the world:

The approval and market launch of ZYNRELEF® can have a broader impact on the healthcare industry and society as a whole. By offering a non-opioid pain relief solution that aligns with CMS Final Rule Non-Opioid Policy, Heron Therapeutics is contributing to the global efforts to combat the opioid crisis and promote safer alternatives for pain management. This can lead to a shift towards more sustainable and effective pain relief options, ultimately benefiting individuals, healthcare systems, and communities worldwide.

Conclusion:

The reported positive financial results and recent corporate updates from Heron Therapeutics highlight the company’s growth and innovation in the biotechnology sector. With the approval and upcoming launch of ZYNRELEF® and its inclusion in CMS Final Rule Non-Opioid Policy, Heron Therapeutics is well-positioned for continued success and positive impact in the healthcare industry.